This report provides insight into AstraZeneca's tech activities, including its digital transformation strategies, its innovation programs, its technology initiatives, its estimated ICT budget, and its major ICT contracts.
AstraZeneca Plc (AstraZeneca) is a biopharmaceutical company, which is focused on discovery, production and commercialization of a range of prescription drugs. It develops products related to therapy areas such as respiratory, cardiovascular, renal and metabolic diseases, cancer, autoimmune, infection, and neurological diseases. The company’s product portfolio includes biologics, prescription pharmaceuticals, and vaccines. AstraZeneca sells its products through wholly-owned local marketing companies, distributors, and local representative offices. The company markets its products to primary care and specialty care physicians.
In April 2022, AstraZeneca India Private Limited (AZIPL), the Global Capability Centre (GCC) of AstraZeneca had repositioned its Global Technology Centre (GTC) to focus on driving innovation, resulting in a rebrand of the center to Global Innovation and Technology Centre (GITC). Over the last eight years, GTC consistently delivered IT services and capabilities for AstraZeneca’s global business, while the center has evolved its offering from traditional IT services, into a critical engine for AstraZeneca’s digital journey of technology innovation.
In May 2023, AstraZeneca joined CleverHealth Network (CHN) led by the Helsinki University Hospital (HUS), to collaborate with existing CHN ecosystem members in developing innovative solutions in health technologies.
- AstraZeneca is building internal IT infrastructure and data analytics capabilities to experiment with both structured and unstructured big data to improve data governance and achieve operational efficiencies. AstraZeneca setup an in-house IT division in India, as part of its strategy to transform and streamline its IT operations.
- AstraZeneca is focusing on building digital factory of the future by testing and creating integrated solutions in its in-house labs. The technology focus of its in-house labs includes image recognition, AI, electronic records, digital twins, robotics, and automation. AstraZeneca operates Healthcare IoT Innovation Center in China responsible for developing smart healthcare solutions to improve patient experience.
- Gain insights into its tech strategies and innovation initiatives.
- Gain insights into its technology themes under focus.
- Gain insights into various product launches, partnerships, and acquisition strategies.
AstraZeneca Plc (AstraZeneca) is a biopharmaceutical company, which is focused on discovery, production and commercialization of a range of prescription drugs. It develops products related to therapy areas such as respiratory, cardiovascular, renal and metabolic diseases, cancer, autoimmune, infection, and neurological diseases. The company’s product portfolio includes biologics, prescription pharmaceuticals, and vaccines. AstraZeneca sells its products through wholly-owned local marketing companies, distributors, and local representative offices. The company markets its products to primary care and specialty care physicians.
In April 2022, AstraZeneca India Private Limited (AZIPL), the Global Capability Centre (GCC) of AstraZeneca had repositioned its Global Technology Centre (GTC) to focus on driving innovation, resulting in a rebrand of the center to Global Innovation and Technology Centre (GITC). Over the last eight years, GTC consistently delivered IT services and capabilities for AstraZeneca’s global business, while the center has evolved its offering from traditional IT services, into a critical engine for AstraZeneca’s digital journey of technology innovation.
In May 2023, AstraZeneca joined CleverHealth Network (CHN) led by the Helsinki University Hospital (HUS), to collaborate with existing CHN ecosystem members in developing innovative solutions in health technologies.
Scope
- AstraZeneca is implementing AI technology to gain better understanding of diseases, identify targets for novel medicines, and enable its scientists to discover and develop new medicines. AstraZeneca launched Machine Learning Ledger Orchestration for Drug Discovery (MELLODDY), a research consortium to leverage machine learning technologies and accelerate drug discovery.- AstraZeneca is building internal IT infrastructure and data analytics capabilities to experiment with both structured and unstructured big data to improve data governance and achieve operational efficiencies. AstraZeneca setup an in-house IT division in India, as part of its strategy to transform and streamline its IT operations.
- AstraZeneca is focusing on building digital factory of the future by testing and creating integrated solutions in its in-house labs. The technology focus of its in-house labs includes image recognition, AI, electronic records, digital twins, robotics, and automation. AstraZeneca operates Healthcare IoT Innovation Center in China responsible for developing smart healthcare solutions to improve patient experience.
Reasons to Buy
- Gain insights into AstraZeneca's tech operations.- Gain insights into its tech strategies and innovation initiatives.
- Gain insights into its technology themes under focus.
- Gain insights into various product launches, partnerships, and acquisition strategies.
Table of Contents
- Overview
- Digital Transformation Strategy
- Accelerators, Incubators, and Other Innovation Programs
- Technology Focus
- Technology Initiatives
- Acquisitions
- Partnership and Acquisition Network Map
- ICT Budget and Contracts
- Key Executives
- Contact Us
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Phyathai 2 Hospital
- Genomenon
- AliveCor
- G42 Healthcare
- NVIDIA
- Mila
- Qure.ai
- Gatehouse Bio
- Schrödinger
- BenevolentAI
- DeepMatter
- BERG
- docdok.health
- IgniteData
- IBM
- DNAnexus
